Atomwise has entered into an evaluation agreement with Pfizer, in which the drug giant will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer.

Atomwise will computationally analyze millions of diverse small molecules for each of Pfizer’s identified target proteins using its AI platform, to predict those that may bind with high affinity to the selected target proteins.

Pfizer will pay a technology access fee and additional success-based payments for each target protein of interest, the companies said in a statement.

[Image courtesy: Atomwise]